Ironwood Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares, representing 8.43% of Ironwood Pharmaceuticals, Inc.'s Class A common stock.
NASDAQ
State Street Corporation has updated its beneficial ownership filing for Ironwood Pharmaceuticals Inc., reporting a significant stake.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares, representing 9.22% of Ironwood Pharmaceuticals, Inc.'s Class A common stock as of March 31, 2026.
NASDAQ
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed a Schedule 13G, reporting beneficial ownership of 4.90% of Ironwood Pharmaceuticals Inc.'s Class A common stock as of March 31, 2026.
NASDAQ
Bank of America Corporation has reported a beneficial ownership of 6.1% in Ironwood Pharmaceuticals Inc. as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Ironwood Pharmaceuticals Inc. following an internal realignment.
NASDAQ
Bank of America Corporation has disclosed a 7.4% beneficial ownership stake in Ironwood Pharmaceuticals Inc.'s Class A Common Stock.
NASDAQ
Barclays PLC has reported a 1.95% beneficial ownership stake in Ironwood Pharmaceuticals Inc., holding 3,167,713 common shares.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.94% of Ironwood Pharmaceuticals Inc.'s Class A common stock.
NASDAQ
Barclays PLC has disclosed a beneficial ownership of 6.88% of Ironwood Pharmaceuticals Inc.'s common stock, totaling 11,133,857 shares, as of June 30, 2025.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 10.01% beneficial ownership stake in Ironwood Pharmaceuticals Inc.'s common stock as of June 30, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.47% of Ironwood Pharmaceuticals Inc.'s Class A common stock, totaling 13,700,000 shares, as of March 31, 2025.
NASDAQ
State Street Corporation has filed a Schedule 13G, reporting a 2.2% beneficial ownership stake in Ironwood Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Pacer Funds Trust and Affiliates Disclose 1.12% Passive Stake in Ironwood Pharmaceuticals
Pacer US Small Cap Cash Cows ETF, Pacer Advisors, Inc., and Joe M. Thomson have jointly filed an amended Schedule 13G, disclosing a passive beneficial ownership of 1.12% in Ironwood Pharmaceuticals Inc.'s Class A Common Stock as of March 31, 2025.
NASDAQ
Pacer US Small Cap Cash Cows ETF, Pacer Advisors, Inc., and Joe M. Thomson have jointly reported a passive beneficial ownership of 7.32% of Ironwood Pharmaceuticals Inc.'s Class A Common Stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Vanguard Group Discloses 9.8% Stake in Ironwood Pharmaceuticals
The Vanguard Group has filed an amended Schedule 13G, revealing a 9.8% beneficial ownership stake in Ironwood Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 7.1% Stake in Ironwood Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc. as of February 28, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 5.92% of Ironwood Pharmaceuticals Inc.'s Class A common stock, totaling 9,468,000 shares.
NASDAQ
State Street Corporation has filed a Schedule 13G, reporting a passive beneficial ownership of 5.2% in Ironwood Pharmaceuticals Inc. as of December 31, 2024.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 12.2% beneficial ownership stake in Ironwood Pharmaceuticals Inc. as of December 31, 2024.